Biosimilars to two of Roche's blockbuster cancer therapies,

...Herceptin and Avastin, launched July 18. The new drugs, Allergan's Kantinti (for Herceptin) and Amgen's Mvasi (for Avastin), are 15% cheaper than their brand-name alternatives, according to the two companies. In the pharmacy benefit, Avastin currently holds preferred status for 13% of covered lives, with Herceptin at 10%.

SOURCE: MMIT Analytics, as of 7/22/19